Statin Therapy Does Not Reduce Liver Fat Scores in Patients Receiving Antiretroviral Therapy for HIV Infection

• Published in: Clinical gastroenterology and hepatology Vol. 17; no. 3; pp. 536 - 542.e1
• Main Authors: El Kamari, Vanessa, Hileman, Corrilynn O., Gholam, Pierre M., Kulkarni, Manjusha, Funderburg, Nicholas, McComsey, Grace A.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.02.2019
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents - administration & dosage; Anti-Retroviral Agents - adverse effects; Antiretroviral Therapy, Highly Active - adverse effects; Antiretroviral Therapy, Highly Active - methods; Double-Blind Method; Fatty Liver; Fatty Liver - pathology; Female; Hepatosteatosis; HIV Infections - drug therapy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage; Male; Middle Aged; Placebos - administration & dosage; Prospective Studies; Treatment Outcome; Viral Load; Virus Infection; Young Adult; AST; NAFLD; ART; ALT; IP-10; Fatty Liver; Virus Infection; HIV; sCD; Hepatosteatosis; SATURN; LFS; NAFLD-FS

Therapies are needed to limit progression of fatty liver diseases in patients with human immunodeficiency virus (HIV) infection. We analyzed data from a prospective study of the effects of rosuvastatin (a statin) on hepatic steatosis in HIV-positive adults. We performed a secondary analysis of data...